

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT4631342

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
UTRECHT UNIVERSITY	06/26/2017
RECEIVING PARTY DATA	
Name:	GlaxoSmithKline Biologicals SA
Street Address:	rue de l'Institut 89
City:	Rixensart
State/Country:	BELGIUM
Postal Code:	B-1330
PROPERTY NUMBERS Total: 2	
Property Type	Number
Patent Number:	9365624
Application Number:	15140879
CORRESPONDENCE DATA	
Fax Number:	(610)270-5090
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	610-270-6812
Email:	US_CIPKOP@GSK.com
Correspondent Name:	GLAXOSMITHKLINE
Address Line 1:	709 SWEDELAND ROAD
Address Line 2:	GP UW2220
Address Line 4:	KING OF PRUSSIA, PENNSYLVANIA 19406
ATTORNEY DOCKET NUMBER:	VB64166
NAME OF SUBMITTER:	ARLENE E CANNON
SIGNATURE:	/Arlene E Cannon/
DATE SIGNED:	10/07/2017
Total Attachments: 3	
source=VB64166 US assignment Utrecht - GSK Bio#page1.tif	
source=VB64166 US assignment Utrecht - GSK Bio#page2.tif	
source=VB64166 US assignment Utrecht - GSK Bio#page3.tif	

PATENT ASSIGNMENT

This assignment is made between:

- (1) **UTRECHT UNIVERSITY**, an institution organized and existing under the laws of the Netherlands, whose registered office is at Heidelberglaan 8, 3508 TC Utrecht, The Netherlands (referred to herein as "**the Assignor**"), and
- (2) **GLAXOSMITHKLINE BIOLOGICALS S.A.** of Rue de l'Institut 89, B-1330 Rixensart, Belgium (referred to herein as "**the Assignee**").

RECITALS

- (A) The Assignor and Assignee are recorded as the joint owners of the patent applications/patents listed in the attached Schedule 1 (collectively referred to herein as "**the Patents**"), which are derived from PCT/EP2011/053665.
- (B) The Assignor has agreed to assign all rights in and to the Patents to the Assignee on the terms set out below


THE TERMS OF THIS AGREEMENT ARE AS FOLLOWS:

- (1) For good and valuable consideration paid by the Assignee to the Assignor (the receipt of which is hereby acknowledged), the Assignor hereby assigns with full title guarantee to the Assignee absolutely the Patents and all rights in and to the Patents, including the right to claim priority from one or more applications, and including the benefit of the applications and further applications, divisions, continuations and continuation-in-parts derived from the Patents, for registration with the intention that, when the applications are granted, the registrations shall vest in the Assignee
- (2) This assignment shall include the right for the Assignee to bring proceedings against any third party in respect of the Patents (including proceedings against any third party for infringement of the Patents).
- (3) The Assignor agrees and undertakes to provide the Assignee (at its request) with all such assistance with any proceedings which may be brought by or against the Assignee against or by a third party in relation to the Patents and the Assignee shall indemnify the Assignor in

respect of all costs and expenses (including reasonable salary and legal costs) incurred by it in providing the Assignee with such assistance.

- (4) The Assignor covenants with the Assignee that, at the expense of the Assignee and at any time and from time to time, they shall execute such deeds or documents and do such acts or things as may be deemed necessary or desirable to give effect to this agreement.

Signed for and on behalf of
Utrecht University



By:


Prof. dr. C.A.C.J. Voeseveldt

Authorized Official of Utrecht University

Dated this

28-06-2017

Signed for and on behalf of
GlaxoSmithKline Biologicals S.A.



By:

CLIVE B THOMPSON

Authorized Official of GlaxoSmithKline

Dated this

14 JUL 2017

VB64166

SCHEDULE 1

Country	Application Date	Application Number	Grant Date	Patent Number
Brazil	11/3/11	BR1120120228005		
Canada	11/3/11	2792691		
China P R	11/3/11	201180022835 1		
European Patent Convention	11/3/11	11708450 9		
India	11/3/11	2877/KOLNP/2012		
Japan	11/3/11	2012-556531		
Japan (Div 1)	23/6/16	2016-124050		
PCT	11/3/11	PCT/EP2011/053665		
United States	11/3/11	13/583419	14/6/16	9365624
United States (Div 1)	28/4/16	15/140879		